The Alzheimer’s Drug Discovery Foundation (ADDF) announces seven new investments, including four clinical trials, two novel drug programs, and a prevention program which reflects the comprehensive nature of its strategy to prevent and treat Alzheimer’s disease and related dementias.
Dr. Howard Fillit, Founding Executive Director and Chief Science Officer of the ADDF, says: “these investments will help us accelerate the development of therapies through our four core areas: clinical trials, drug discovery, biomarkers, and prevention.” Dr. Fillit notes that the new investments cover diverse forms of dementia ranging from a novel treatment for postoperative cognitive dysfunction and delirium, and therapies for frontotemporal degeneration that target both epigenetics and neuroinflammation. Another investment will be used to build and test web-based online education…
